Circulating PD-1(+)CXCR5(-)CD4(+) T cells underlying the immunological mechanisms of IgG4-related disease

循环中的PD-1(+)CXCR5(-)CD4(+) T细胞是IgG4相关疾病免疫机制的基础。

阅读:1

Abstract

OBJECTIVE: The aim was to study the pathological role of lymphocytes with a peripheral T helper-cell-like phenotype (PD-1(+)CXCR5(-)CD4(+)) in IgG4-related disease (IgG4-RD). METHODS: PD-1(+)CXCR5(-)CD4(+) T cells in the blood of patients with IgG4-RD (n = 53), patients with SS (n = 16) and healthy volunteers (n = 34) as controls were analysed by flow cytometry. Correlations between results obtained by flow cytometry and clinical parameters relevant to IgG4-RD were also analysed. RESULTS: The percentage and absolute number of PD-1(+)CXCR5(-) cells within total CD4(+) T cells in IgG4-RD patients were significantly increased compared with those in healthy volunteers. Further analysis showed that there were marked positive correlations of the percentage of PD-1(+)CXCR5(-)CD4(+) T cells with the serum level of IgG4 and the number of organs involved. Interestingly, granzyme A (GZMA)(+) cells were enriched in PD-1(+)CXCR5(-)CD4(+) T cells, and the percentage and absolute number of GZMA(+)PD-1(+)CXCR5(-)CD4(+) T cells were significantly elevated in IgG4-RD patients. Although no obvious change was observed in the percentage of total CD4(+) T cells, the percentage and absolute number of PD-1(+)CXCR5(-)CD4(+) T cells decreased in accordance with a reduction of serum IgG4 level after treatment with glucocorticoids. CONCLUSION: In IgG4-RD, circulating CD4(+) T-cell populations were composed of PD-1(+)CXCR5(-) cells, and the ratios of these cells were correlated with clinical manifestations of IgG4-RD. Further analysis of GZMA(+)PD-1(+)CXCR5(-)CD4(+) T cells might lead to a deeper understanding of the pathogenesis of ectopic lymphoid follicles and the persistent inflammation in IgG4-RD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。